Duration of First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent Therapies
- 20 November 2007
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (33), 5155-5157
- https://doi.org/10.1200/jco.2007.13.4015
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trialLung Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004